Urokinase-type Plasminogen Activator (uPA)

Urokinase-type Plasminogen Activator (uPA) is a 52-kDa serine proteinase. Active uPA rapidly converts the inactive plasmin precursor, plasminogen, to enzymatically active plasmin, which is directly involved in extracellular matrix degradation as well as in the activation of other procollagenases and latent growth factors. It is expressed in the prostate gland and prostate cancers. uPA is available commercially under the name Abbokinase (Abbott) and is used clinically for therapy of thrombolytic disorders such as pulmonary embolism where it initiates fibrinolysis.

Swiss-Prot Accession Number: P00749


Myriad RBM Publications Publications
Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-ßRI inhibitor galunisertib. (2020) Giannelli G, Santoro A, Kelley RK, Gane E, Paradis V, Cleverly A, Smith C, Estrem ST, Man M, Wang S, Lahn MM, Raymond E, Benhadji KA, Faivre S PLoS One
Major depression and enhanced molecular senescence abnormalities in young and middle-aged adults. (2019) Diniz BS, Reynolds Iii CF, Sibille E, Bot M, Penninx BWJH Translational Psychiatry
Novel Biomarkers for Change in Renal Function in People With Dysglycemia. (2019) Gerstein HC, Pare G, McQueen MJ, Lee SF, Bangdiwala SI, Kannt A, Hess A, ORIGIN Trial Investigators Diabetes Care
Dendritic cell immunotherapy followed by cART interruption during HIV-1 infection induces plasma protein markers of cellular immunity and neutrophil recruitment (2018) van den Ham HJ, Cooper J, Tomasik J, Bahn S, Aerts J, Oseterhaus A, Gruters R, Andeweg A PLoS One
Variation in Serum Biomarkers with Sex and Female Hormonal Status: Implications for Clinical Tests (2016) Ramsey JM, Cooper JD, Penninx BWJH, Bahn S Scientific Reports